Evidence map›Paper›PMID 41073503›Full record

Trial reportScientific reports2025

Rituximab-induced long-term remission in childhood-onset, uncomplicated, frequently relapsing or steroid-dependent nephrotic syndrome: a randomized, placebo-controlled trial and a follow-up study.

Kazumoto Iijima, Mayumi Sako, Tomoko Horinouchi, Tomoyuki Sakai, Tomohiko Yamamura, Riku Hamada, Yasufumi Ohtsuka, Seiji Tanaka, Koichi Kamei, Ryojiro Tanaka and 19 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Kazumoto Iijima *Hyogo Prefectural Kobe Children's Hospital, Minatojimaminami-machi 1-6-7, Chuo-ku, Kobe, Hyogo, 650-0047, Japan. iijima@med.kobe-u.ac.jp.
Mayumi Sako *Department of Clinical Research Promotion, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.
Tomoko Horinouchi *Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Tomoyuki SakaiDepartment of Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan.
Tomohiko YamamuraDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Riku HamadaDepartment of Nephrology and Rheumatology, Tokyo Metropolitan Children's Medical Center, Fuchu, Tokyo, Japan.
Yasufumi OhtsukaDepartment of Pediatrics, Faculty of Medicine, Saga University, Saga City, Saga, Japan.
Seiji TanakaDepartment of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Koichi KameiDivision of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.
Ryojiro TanakaDepartment of Nephrology, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan.
Yuji KanoDepartment of Pediatrics, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan.
Takuo KubotaDepartment of Pediatrics, Graduate School of Medicine, The University of Osaka, Suita, Osaka, Japan.
Yuko ShimaDepartment of Pediatrics, Wakayama Medical University, Wakayama City, Wakayama, Japan.
Tamaki MorohashiDepartment of Pediatrics, Nihon University School of Medicine, Tokyo, Japan.
Aya InabaDepartment of Pediatrics, Graduate School of Medicine, Yokohama City University, Yokohama, Kanagawa, Japan.
Shuichiro FujinagaDivision of Nephrology, Saitama Children's Medical Center, Saitama City, Saitama, Japan.
Masafumi OkaDepartment of Pediatrics, Faculty of Medicine, Saga University, Saga City, Saga, Japan.
Hiroshi KaitoDepartment of Nephrology, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan.
Akihide KonishiClinical and Translational Research Center, Kobe University Hospital, Kobe, Hyogo, Japan.
China NaganoDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Koichi NakanishiDepartment of Child Health and Welfare (Pediatrics), Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan.
Kenji IshikuraDepartment of Pediatrics, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Shuichi ItoDepartment of Pediatrics, Graduate School of Medicine, Yokohama City University, Yokohama, Kanagawa, Japan.
Hidefumi NakamuraClinical Research Center, National Center for Child Health and Development, Tokyo, Japan.
Gian Marco GhiggeriDivision of Nephrology, Dialysis, Transplantation, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Rintaro MoriGraduate School of Medicine, Kyoto University, Kyoto, Japan.
Takashi OmoriClinical and Translational Research Center, Kobe University Hospital, Kobe, Hyogo, Japan.
Kandai Nozu *Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Japanese Study Group of Kidney Disease in Children JSKDC10 Study

Funding

Zenyaku Kogyo Co., Ltd. JSKDC10
6 · The paper itself

Abstract

Rituximab maintains remission of complicated frequently relapsing or steroid-dependent nephrotic syndrome (FRNS/SDNS) by depleting peripheral B cells, but most patients eventually experience relapses after B cell recovery. We performed a multicenter, double-blind, randomized, placebo-controlled trial to assess rituximab's efficacy and safety for childhood-onset uncomplicated FRNS/SDNS (without prior treatment with glucocorticoid-sparing immunosuppressive agents) with a follow-up study to assess rituximab's long-term effect after B cell recovery. Patients were randomly assigned to receive either rituximab (375 mg/m

Indexed as

Immunologic FactorsNephrotic SyndromeRituximabAdolescentChildChild, PreschoolDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleRecurrenceRemission InductionSteroidsTreatment OutcomeImmunologic FactorsRituximabSteroidsChildrenLong-term remissionRituximabUncomplicated frequently relapsing or steroid-dependent nephrotic syndrome

Identifiers

PMID41073503
PMCPMC12514064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.